Latest News about GILD
Recent news which mentions GILD
From Benzinga
This Gilead Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
October 17, 2024
From Benzinga
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
From Benzinga
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
October 07, 2024
From Benzinga
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
October 07, 2024
From Benzinga
From Benzinga
Top 4 Health Care Stocks That May Keep You Up At Night
September 24, 2024
From Benzinga
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
September 23, 2024
From Benzinga
3 Dirt Cheap Stocks to Buy Right Now
September 21, 2024
From Motley Fool
Gilead Sciences Unusual Options Activity For September 20
September 20, 2024
Tickers
GILD
From Benzinga
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
September 20, 2024
From Benzinga
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
September 14, 2024
From Motley Fool
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
September 13, 2024
From Benzinga
Why Gilead Sciences Stock Thrashed the Market Today
September 12, 2024
Tickers
GILD
From Motley Fool
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
September 12, 2024
From Benzinga
What the Options Market Tells Us About Gilead Sciences
September 12, 2024
Tickers
GILD
From Benzinga
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
September 03, 2024
From Benzinga
Gilead Sciences Options Trading: A Deep Dive into Market Sentiment
September 03, 2024
Tickers
GILD
From Benzinga
From Benzinga
Gilead's Ongoing Battle Against Counterfeit HIV Medications Persists With New Lawsuit, Seizes $750K In Fake Drugs
August 16, 2024
From Benzinga
FDA Approves Gilead's Seladelpar For Inflammatory Liver Disease, Acquired Via $4B CymaBay Deal
August 15, 2024
From Benzinga
Expert Outlook: Gilead Sciences Through The Eyes Of 8 Analysts
August 15, 2024
Tickers
GILD
From Benzinga
7 Defensive Stocks to Buy as Investors Seek Shelter
August 14, 2024
From InvestorPlace
3 Stocks Retirees Should Absolutely Love
August 10, 2024
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.